Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) by human mast cell tryptase

British Journal of Pharmacology
S J ComptonMorley D Hollenberg

Abstract

1. Human mast cell tryptase appears to display considerable variation in activating proteinase-activated receptor 2 (PAR(2)). We found tryptase to be an inefficient activator of wild-type rat-PAR(2) (wt-rPAR(2)) and therefore decided to explore the factors that may influence tryptase activation of PAR(2). 2. Using a 20 mer peptide (P20) corresponding to the cleavage/activation sequence of wt-rPAR(2), tryptase was as efficient as trypsin in releasing the receptor-activating sequence (SLIGRL.). However, in the presence of either human-PAR(2) or wt-r PAR(2) expressing cells, tryptase could only activate PAR(2) by releasing SLIGRL from the P20 peptide, suggesting that PAR(2) expressed on the cells was protected from tryptase activation. 3. Three approaches were employed to test the hypothesis that PAR(2) receptor glycosylation restricts tryptase activation. (a) pretreatment of wt-rPAR(2) expressing cells or human embryonic kidney cells (HEK293) with vibrio cholerae neuraminidase to remove oligosaccharide sialic acid, unmasked tryptase-mediated PAR(2) activation. (b) Inhibiting receptor glycosylation in HEK293 cells with tunicamycin enabled tryptase-mediated PAR(2) activation. (c) Wt-rPAR(2) devoid of the N-terminal glycosylation se...Continue Reading

References

Jul 8, 1975·Biochemical and Biophysical Research Communications·J S Tkacz, O Lampen
Aug 1, 1991·The Journal of Clinical Investigation·S J RuossG H Caughey
Sep 1, 1990·The Journal of Clinical Investigation·J S MillerL B Schwartz
Sep 1, 1990·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·A F WallsM K Church
Aug 1, 1995·American Journal of Respiratory Cell and Molecular Biology·J K BrownG H Caughey
Jan 26, 1995·Biochemical and Biophysical Research Communications·A TordaiE W Gelfand
Feb 14, 1997·The Journal of Biological Chemistry·M MolinoL F Brass
Mar 15, 1997·The Journal of Clinical Investigation·J A Cairns, A F Walls
Jun 5, 1997·European Journal of Pharmacology·S He, A F Walls
Aug 5, 1997·Proceedings of the National Academy of Sciences of the United States of America·W KongN W Bunnett
Sep 18, 1997·The Journal of Clinical Investigation·C U CorveraN W Bunnett
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·W F XuD C Foster
Jun 5, 1998·The American Journal of Physiology·O DéryN W Bunnett
Aug 26, 1998·Nature·M L KahnS R Coughlin
Mar 29, 2000·Proceedings of the National Academy of Sciences of the United States of America·C NapoliG Cirino
Apr 15, 2000·Nature·M Nakanishi-MatsuiS R Coughlin
Aug 17, 2000·Biochemical and Biophysical Research Communications·A K AlmJ Sundelin

❮ Previous
Next ❯

Citations

Dec 16, 2011·Pflügers Archiv : European journal of physiology·Juraj RievajHarissios Vliagoftis
Nov 26, 2003·European Journal of Pharmacology·Vassiliki GiannoulakiEkaterini Tiligada
Sep 24, 2002·Pharmacology & Therapeutics·Rommel S LanPeter J Henry
Oct 7, 2004·International Archives of Allergy and Immunology·Harissios VliagoftisRedwan Moqbel
Mar 21, 2006·American Journal of Respiratory Cell and Molecular Biology·Michel Chignard, Dominique Pidard
Feb 25, 2006·American Journal of Respiratory Cell and Molecular Biology·Rithwik RamachandranSteven J Compton
May 14, 2008·American Journal of Respiratory Cell and Molecular Biology·Jeong Hee HongDong Min Shin
Feb 21, 2003·American Journal of Respiratory Cell and Molecular Biology·Sophie DulonDominique Pidard
May 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kristina K HansenNathalie Vergnolle
Feb 1, 2011·Pharmacology & Therapeutics·Mark N AdamsJohn D Hooper
Jun 2, 2009·Pharmacology & Therapeutics·Nathalie Vergnolle
Nov 6, 2007·Trends in Immunology·V ShpacovitchM Steinhoff
Nov 28, 2007·International Immunopharmacology·Yoshihiro Fukuoka, Lawrence B Schwartz
Aug 16, 2005·British Journal of Pharmacology·Steeve HouleNathalie Vergnolle
Apr 28, 2006·The FEBS Journal·Jenny Hallgren, Gunnar Pejler
Sep 1, 2007·Journal of Cellular and Molecular Medicine·Ken A LindstedtPetri T Kovanen
Aug 14, 2008·Allergy·A B VrolingC M van Drunen
Aug 28, 2015·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M AsaduzzamanH Vliagoftis
Sep 27, 2005·Vascular Pharmacology·Mariarosaria BucciGiuseppe Cirino
Mar 28, 2006·Biochimica Et Biophysica Acta·Yongjie MaLianhua Yin
May 27, 2014·Frontiers in Endocrinology·Peishen ZhaoNigel W Bunnett
Sep 30, 2016·Pharmacological Reviews·Rithwik RamachandranMorley D Hollenberg
Apr 21, 2017·Expert Opinion on Therapeutic Patents·Wei-Wei NiJi-Fu Wei
May 28, 2010·Journal of Dental Research·F T LundyI A El Karim
Jan 17, 2004·The Journal of Biological Chemistry·Graeme S CottrellNigel W Bunnett
Mar 27, 2004·Physiological Reviews·Valeria S Ossovskaya, Nigel W Bunnett
Aug 11, 2005·Canadian Journal of Physiology and Pharmacology·Michelle L SeymourWallace K MacNaughton
Sep 13, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·James K BrownCary A Jones
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bahjat Al-AniMorley D Hollenberg
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Bahjat Al-Ani, Morley D Hollenberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.